AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11820726 — intervention group
Group type: EXPERIMENTAL
Intervention: Occluded application of aqueous enzyme solution
Number of subjects: 0
Study 11820726 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step unoccluded application of aqueous enzyme solution followed by commercial moisturizer
Number of subjects: 0
Study 9428539 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral formula (control group; n = 55)
Number of subjects: 166
Study 9428539 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched enteral formula (n = 55)
Number of subjects: 166
Study 9428539 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN group; n = 56)
Number of subjects: 166
Study 8002923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 8002923 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET)
Number of subjects: 0
Study 8002923 — intervention group
Group type: COMPARATOR
Intervention: Nontreated control group
Number of subjects: 0
Study 2681770 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressings containing purified angiogenic and growth factors from human term placenta
Number of subjects: 18
Study 2681770 — intervention group
Group type: COMPARATOR
Intervention: Dressings not containing purified angiogenic and growth factors
Number of subjects: 18
Study 4758487 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine cigarettes (<0.3 mg)
Number of subjects: 10
Study 4758487 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine cigarettes (3.2 mg)
Number of subjects: 10
Study 4758487 — intervention group
Group type: COMPARATOR
Intervention: Usual brand cigarettes
Number of subjects: 10
Study 31855493 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion Peel Extract (OPE)
Number of subjects: 100
Study 31855493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30394960 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver education (educational session for recognizing early symptoms/signs of heart failure, with recording in a diary of patient parameters)
Number of subjects: 313
Study 30394960 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver education
Number of subjects: 313
Study 30394960 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 313
Study 27710139 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 866
Study 25847690 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-1992 (extended-release carbidopa/levodopa), 2 times per day
Number of subjects: 34
Study 25847690 — intervention group
Group type: COMPARATOR
Intervention: CD/L-dopa IR (immediate-release carbidopa/levodopa), 4.8 times per day
Number of subjects: 34
Study 25847690 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-1992
Number of subjects: 34
Study 25847690 — intervention group
Group type: COMPARATOR
Intervention: CD/L-dopa IR
Number of subjects: 34
Study 23940575 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat-based whole grain foods
Number of subjects: 206
Study 23940575 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat + oats-based whole grain foods
Number of subjects: 206
Study 23940575 — intervention group
Group type: COMPARATOR
Intervention: Control (refined diet)
Number of subjects: 206
Study 21745038 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (HF; 40% energy from fat)
Number of subjects: 0
Study 21745038 — intervention group
Group type: COMPARATOR
Intervention: Low fat plus n-3 FA diet (LFn3; 20% of energy from fat plus 3% of energy from n-3 FA)
Number of subjects: 0
Study 19654956 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral uridine
Number of subjects: 27
Study 19654956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16740612 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dietary sodium intake (10 mmol day(‐1)) for 5 days in Gly16 group
Number of subjects: 32
Study 16740612 — intervention group
Group type: COMPARATOR
Intervention: Low dietary sodium intake (10 mmol day(‐1)) for 5 days in Arg16 group
Number of subjects: 32
Study 16740612 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic administration of intravenous terbutaline (TRB)
Number of subjects: 32
Study 16740612 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm blood flow (FBF) response to incremental doses of isoprenaline
Number of subjects: 32
Study 15478443 — intervention group
Group type: EXPERIMENTAL
Intervention: Categories with a boundary coincident with the perceptual discontinuity
Number of subjects: 0
Study 15478443 — intervention group
Group type: COMPARATOR
Intervention: Categories defined such that the perceptual discontinuity fell within a category
Number of subjects: 0
Study 11227395 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 to 20 mg/day
Number of subjects: 150
Study 11227395 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 4 to 12 mg/day
Number of subjects: 150
Study 9024451 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (4 mg/kg per day)
Number of subjects: 141
Study 9024451 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroid treatment
Number of subjects: 141
Study 8420726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (n = 65) as an iv infusion of 50 to 100 mg/hr
Number of subjects: 131
Study 8420726 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 131
Study 8420726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (n = 65)
Number of subjects: 131
Study 8420726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (n = 56)
Number of subjects: 131
Study 8420726 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 61)
Number of subjects: 131
Study 6981177 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) intravenously for at least four days or orally for at least nine days (total daily dose, 10-20 mg/kg)
Number of subjects: 0
Study 6981177 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) therapy
Number of subjects: 0
Study 6981177 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial intravenous therapy with doses of 15-20 mg/kg per day
Number of subjects: 0
Study 6981177 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 0
Study 31155969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Oriented Strategy Training Augmented Rehabilitation (COSTAR)
Number of subjects: 44
Study 31155969 — intervention group
Group type: COMPARATOR
Intervention: Task-Specific Training (TST)
Number of subjects: 44
Study 31639320 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum nasal feedback condition
Number of subjects: 20
Study 31639320 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum nasal feedback condition
Number of subjects: 20
Study 31639320 — intervention group
Group type: COMPARATOR
Intervention: Baseline feedback conditions
Number of subjects: 20
Study 28109298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous G-CSF followed by mPBMC infusion
Number of subjects: 57
Study 28109298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous G-CSF followed by mPBMC infusion at 7 months (T7 group)
Number of subjects: 57
Study 28109298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous G-CSF followed by mPBMC infusion at 1 month (T1 group)
Number of subjects: 57
Study 28109298 — intervention group
Group type: COMPARATOR
Intervention: mPBMC infusion
Number of subjects: 57
Study 28109298 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 57
Study 25426510 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP trial (4 maximal 10-m swims at 1-minute intervals before a 6-minute rest)
Number of subjects: 30
Study 25426510 — intervention group
Group type: COMPARATOR
Intervention: Control trial (standard swim warm-up followed by a 6-minute rest and maximal 100-m freestyle swim effort)
Number of subjects: 30
Study 24554302 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin (600 mg once a week for 12 weeks)
Number of subjects: 152
Study 24554302 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin (3 g once a week for 12 weeks)
Number of subjects: 152
Study 24554302 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin and Fosfomycin (both groups)
Number of subjects: 152
Study 21636230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with clarithromycin (200mg/day) and S-carboxymethylcysteine (1500mg/day) for 12 weeks
Number of subjects: 425
Study 21636230 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with clarithromycin (200mg/day) for 12 weeks
Number of subjects: 425
Study 21636230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with clarithromycin and S-carboxymethylcysteine
Number of subjects: 425
Study 21636230 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (combination and monotherapy)
Number of subjects: 425
Study 19489132 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg HFA-BDP bid for 12 weeks
Number of subjects: 38
Study 19489132 — intervention group
Group type: COMPARATOR
Intervention: 400 mcg CFC-BDP bid for 12 weeks
Number of subjects: 38
Study 19489132 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP
Number of subjects: 38
Study 17407649 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors as monotherapy
Number of subjects: 0
Study 17407649 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors as add-on therapy
Number of subjects: 0
Study 17407649 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors
Number of subjects: 0
Study 16874208 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure therapy
Number of subjects: 65
Study 16874208 — intervention group
Group type: COMPARATOR
Intervention: Modern dressings
Number of subjects: 65
Study 12780372 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated tailored advice plus callback telephone counselling
Number of subjects: 1578
Study 12780372 — intervention group
Group type: COMPARATOR
Intervention: Computer-generated tailored advice only
Number of subjects: 1578
Study 12780372 — intervention group
Group type: COMPARATOR
Intervention: Control condition (untailored self-help materials)
Number of subjects: 1578
Study 12780372 — intervention group
Group type: EXPERIMENTAL
Intervention: Callback telephone counselling
Number of subjects: 1578
Study 12780372 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated tailored advice
Number of subjects: 1578
Study 12780372 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT (nicotine replacement therapy)
Number of subjects: 1578
Study 12780372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained abstinence
Number of subjects: 1578
Study 10224730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CB)
Number of subjects: 116
Study 10224730 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic-interpersonal therapy (PI)
Number of subjects: 116
Study 8936558 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of vitamin E per day
Number of subjects: 21
Study 8936558 — intervention group
Group type: COMPARATOR
Intervention: 1 g of vitamin C per day
Number of subjects: 21
Study 8936558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1826239 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinsulin
Number of subjects: 15
Study 6193665 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of dextran 1, 15% administered intravenously two minutes before infusion of dextran 70 or dextran 40
Number of subjects: 29252
Study 6193665 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of dextran 1, 15%
Number of subjects: 29252
Study 31046075 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 38
Study 28421567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment (28 tablets of 1000 µg cyanocobalamin per month)
Number of subjects: 37
Study 28421567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular treatment (four weekly injections of 1000 µg hydroxocobalamin)
Number of subjects: 37
Study 28421567 — intervention group
Group type: COMPARATOR
Intervention: Oral treatment
Number of subjects: 37
Study 28421567 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular treatment
Number of subjects: 37
Study 25041291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg once daily
Number of subjects: 50
Study 25041291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23793444 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) with radiofrequency or cryoenergy
Number of subjects: 205
Study 23793444 — intervention group
Group type: EXPERIMENTAL
Intervention: LA pressure
Number of subjects: 205
Study 23793444 — intervention group
Group type: EXPERIMENTAL
Intervention: LA volume index
Number of subjects: 205
Study 23793444 — intervention group
Group type: EXPERIMENTAL
Intervention: AF type
Number of subjects: 205
Study 21882997 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based behavioral weight loss program with weekly group meetings delivered entirely by online synchronous chats
Number of subjects: 323
Study 21882997 — intervention group
Group type: COMPARATOR
Intervention: Internet-based behavioral weight loss program with weekly group meetings delivered by a combination of online chats plus monthly in-person group sessions
Number of subjects: 323
Study 18387865 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound instillation with ropivacaine 0.2%
Number of subjects: 17
Study 18387865 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 17
Study 17022844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole 0.25‐4.0 mg once daily 1‐3 hours before bedtime
Number of subjects: 0
Study 17022844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12630974 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp)
Number of subjects: 17
Study 12630974 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Insulin (HI)
Number of subjects: 17
Study 10866717 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 14
Study 10866717 — intervention group
Group type: COMPARATOR
Intervention: 3% sevoflurane
Number of subjects: 14
Study 9114180 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin or metronidazole for active C. difficile diarrhea
Number of subjects: 124
Study 9114180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential episodes of C. difficile diarrhea
Number of subjects: 124
Study 9114180 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for RCDD
Number of subjects: 124
Study 1549227 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (average doses: 5 to 10, 10 to 20, and 20 to 40 units per muscle)
Number of subjects: 17
Study 1549227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1549227 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 17
Study 4044293 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 12
Study 4044293 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 12
Study 31179007 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day antibiotic treatment
Number of subjects: 1101
Study 31179007 — intervention group
Group type: COMPARATOR
Intervention: 3-day placebo treatment
Number of subjects: 1101
Study 31179007 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' education levels
Number of subjects: 1101
Study 28977390 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg methylprednisolone
Number of subjects: 120
Study 28977390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26775230 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterned electrical neuromuscular stimulation
Number of subjects: 15
Study 26775230 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 15
Study 25300507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0
Study 25300507 — intervention group
Group type: COMPARATOR
Intervention: Verteporfin photodynamic therapy (vPDT)
Number of subjects: 0
Study 25300507 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 0
Study 22508360 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% (w/v) honey solution
Number of subjects: 101
Study 22508360 — intervention group
Group type: COMPARATOR
Intervention: 0.3% ofloxacin
Number of subjects: 101
Study 19854494 — intervention group
Group type: EXPERIMENTAL
Intervention: DUR-8E
Number of subjects: 175
Study 19854494 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Viper
Number of subjects: 175
Study 19854494 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexVision
Number of subjects: 175
Study 19854494 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympus URF-P5
Number of subjects: 175
Study 18005909 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs (30 drops, 1.5 mL, three times a day for a maximum of 10 days)
Number of subjects: 103
Study 18005909 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times a day for a maximum of 10 days)
Number of subjects: 103
Study 18005909 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs
Number of subjects: 103
Study 18005909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 18005909 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in EPs group
Number of subjects: 103
Study 16118171 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiography followed by a short MR imaging examination
Number of subjects: 500
Study 16118171 — intervention group
Group type: COMPARATOR
Intervention: Radiography alone
Number of subjects: 500
Study 11230472 — intervention group
Group type: EXPERIMENTAL
Intervention: suramin plus hydrocortisone
Number of subjects: 460
Study 11230472 — intervention group
Group type: COMPARATOR
Intervention: placebo plus hydrocortisone
Number of subjects: 460
Study 9563220 — intervention group
Group type: EXPERIMENTAL
Intervention: metronidazole (400 mg t.i.d. for 7 days)
Number of subjects: 32
Study 9563220 — intervention group
Group type: EXPERIMENTAL
Intervention: secnidazole (500 mg t.i.d. for 5 days)
Number of subjects: 32
Study 9563220 — intervention group
Group type: COMPARATOR
Intervention: metronidazole
Number of subjects: 32
Study 9563220 — intervention group
Group type: COMPARATOR
Intervention: secnidazole
Number of subjects: 32
Study 7996065 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Number of subjects: 136
Study 7996065 — intervention group
Group type: COMPARATOR
Intervention: High dose methylprednisolone
Number of subjects: 136
Study 7996065 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose steroids
Number of subjects: 136
Study 3131798 — intervention group
Group type: EXPERIMENTAL
Intervention: sabeluzole (R 58735)
Number of subjects: 20
Study 3131798 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 31644389 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention (BASICS)
Number of subjects: 51
Study 31644389 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intervention (BASICS)
Number of subjects: 51
Study 29778364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg twice a day)
Number of subjects: 1534
Study 29778364 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg once a day)
Number of subjects: 1534
Study 29778364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol plus probucol (250 mg twice a day)
Number of subjects: 1534
Study 29778364 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus probucol
Number of subjects: 1534
Study 28142074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) treatment on scan 2
Number of subjects: 0
Study 28142074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) treatment
Number of subjects: 0
Study 28142074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26226536 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive QL intervention with up to an 8-week supply of free nicotine replacement therapy
Number of subjects: 1298
Study 26226536 — intervention group
Group type: COMPARATOR
Intervention: Reactive QL intervention with a 2-week supply of nicotine replacement therapy
Number of subjects: 1298
Study 22814361 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims data for fecal occult blood testing
Number of subjects: 400
Study 22814361 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims data for colonoscopy
Number of subjects: 400
Study 22814361 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims data for sigmoidoscopy
Number of subjects: 400
Study 22814361 — intervention group
Group type: EXPERIMENTAL
Intervention: Over- and underdocumentations of colonoscopy and fecal occult blood testing
Number of subjects: 400
Study 21907619 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided game warm-up
Number of subjects: 10
Study 21907619 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg-press warm-up
Number of subjects: 10
Study 21907619 — intervention group
Group type: COMPARATOR
Intervention: Team-sport warm-up
Number of subjects: 10
Study 18276664 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group education programme for six hours delivered in the community by trained healthcare professional educators
Number of subjects: 824
Study 18276664 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 824
Study 18276664 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group education programme
Number of subjects: 824
Study 17044457 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Fluconazole (100-200 mg/day for one week)
Number of subjects: 23
Study 17044457 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (stable dosage)
Number of subjects: 23
Study 12850655 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management intervention by Depression Clinical Specialists (DCSs)
Number of subjects: 13
Study 10379287 — intervention group
Group type: EXPERIMENTAL
Intervention: EPi‐Guide
Number of subjects: 40
Study 10379287 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidor
Number of subjects: 40